Recently, inhibitors [eg. sotorasib (AMG510) and adagrasib (MRTX849)] that covalently bind to the cysteine of the glycine- 12-cysteine (G12 C) substitution of KRASG12MT, reported in 2–4% of mCRC [46], in combination with EGFR monoclonal antibodies (CodeBreaK300 [47]; KRYSTAL- 1 [48] have shown promising results in heavily pre-treated CRC patients. Here, EGFR is linked to colorectal carcinoma.